Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial

Faculty Opinions recommendation of Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.739122585.793581022 ◽

2020 ◽

Author(s):

Otto Hemminki

Keyword(s):

Clinical Trial ◽

Gene Therapy ◽

Bladder Cancer ◽

Invasive Bladder Cancer ◽

Repeat Dose ◽

Open Label ◽

Re: Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Single-arm, Open-label, Repeat-dose Clinical Trial

European Urology ◽

10.1016/j.eururo.2021.01.027 ◽

2021 ◽

Author(s):

Francesco Soria ◽

Paolo Gontero

Keyword(s):

Clinical Trial ◽

Gene Therapy ◽

Bladder Cancer ◽

Invasive Bladder Cancer ◽

Repeat Dose ◽

Open Label ◽

Re: Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Single-arm, Open-label, Repeat-dose Clinical Trial

European Urology ◽

10.1016/j.eururo.2021.02.015 ◽

2021 ◽

Author(s):

Markus Grabbert ◽

Roland Seiler ◽

Christian Gratzke

Keyword(s):

Clinical Trial ◽

Gene Therapy ◽

Bladder Cancer ◽

Invasive Bladder Cancer ◽

Repeat Dose ◽

Open Label ◽

Results of the phase-I open-label clinical trial SAKK 06/14 assessing safety of intravesical instillation of the recombinant BCG VPM1002BC in patients with non-muscle invasive bladder cancer and previous failure to conventional BCG therapy

European Urology Supplements ◽

10.1016/s1569-9056(18)31563-x ◽

2018 ◽

Vol 17 (2) ◽

pp. e1050 ◽

Cited By ~ 5

Author(s):

C. Rentsch ◽

P. Bosshard ◽

G. Mayor ◽

M. Rieken ◽

H. Püschel ◽

...

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

Phase I ◽

Intravesical Instillation ◽

Invasive Bladder Cancer ◽

Open Label ◽

Bcg Therapy ◽

Muscle Invasive ◽

Recombinant Bcg

Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy

OncoImmunology ◽

10.1080/2162402x.2020.1748981 ◽

2020 ◽

Vol 9 (1) ◽

pp. 1748981 ◽

Cited By ~ 3

Author(s):

Cyrill A. Rentsch ◽

Piet Bosshard ◽

Grégoire Mayor ◽

Malte Rieken ◽

Heike Püschel ◽

...

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

Phase I ◽

Intravesical Instillation ◽

Invasive Bladder Cancer ◽

Bacillus Calmette Guerin ◽

Open Label ◽

Bcg Therapy ◽

A phase I open label dose‐escalation study to evaluate the tolerability, safety and immunological efficacy of sub‐urothelial durvalumab injection in adults with muscle‐invasive or high‐risk non‐muscle‐invasive bladder cancer (SUBDUE‐1, SUB‐urothelial DUrvalumab injection‐1 study): clinical trial protocol

BJU International ◽

10.1111/bju.15365 ◽

2021 ◽

Author(s):

Andrew Moe ◽

Elizabeth Liow ◽

Andrew Redfern ◽

Nicole Swarbrick ◽

Tom Ferguson ◽

...

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

High Risk ◽

Phase I ◽

Trial Protocol ◽

Open Label ◽

Dose Escalation Study ◽

Label Dose ◽

The effect of a neoadjuvant instillation of chemotherapy in the prevention of recurrences of non-muscle invasive bladder cancer. Preliminary results of the PRECAVE prospective, controlled, randomized clinical trial

European Urology ◽

10.1016/s0302-2838(21)01132-5 ◽

2021 ◽

Vol 79 ◽

pp. S1043-S1044

Author(s):

D.M. Carrión Monsalve ◽

J. Gomez Rivas ◽

C.R. Trelles ◽

C. Ballesteros Ruiz ◽

M. Alvarez-Maestro ◽

...

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

Randomized Clinical Trial ◽

Invasive Bladder Cancer ◽

Preliminary Results ◽

Diagnostic performance of the Bladder EpiCheck methylation test and photodynamic diagnosis-guided cystoscopy in the surveillance of high-risk non-muscle invasive bladder cancer: A single centre, prospective, blinded clinical trial

Urologic Oncology Seminars and Original Investigations ◽

10.1016/j.urolonc.2021.11.001 ◽

2021 ◽

Author(s):

Giovanni Cochetti ◽

Jacopo Adolfo Rossi de Vermandois ◽

Vincenza Maulà ◽

Luigi Cari ◽

Rosy Cagnani ◽

...

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

High Risk ◽

Diagnostic Performance ◽

Invasive Bladder Cancer ◽

Photodynamic Diagnosis ◽

Single Centre ◽

The benefit of a neoadjuvant instillation of chemotherapy in non-muscle invasive bladder cancer: interim analysis of the PRECAVE randomized clinical trial.

10.37554/en-j.arch.esp.urol-20210704-3511-30 ◽

2021 ◽

Author(s):

Diego Carrión ◽

Juan Gómez Rivas ◽

Cristina Ballesteros Ruiz ◽

Mario Álvarez-Maestro ◽

Emilio Ríos González ◽

...

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

Randomized Clinical Trial ◽

Interim Analysis ◽

Invasive Bladder Cancer ◽

Adjuvant recMAGE-A3 Immunotherapy After Cystectomy for Muscle-invasive Bladder Cancer: Lessons Learned from the Phase 2 MAGNOLIA Clinical Trial

European Urology Focus ◽

10.1016/j.euf.2018.02.005 ◽

2019 ◽

Vol 5 (5) ◽

pp. 849-852

Author(s):

Peter F.A. Mulders ◽

Luis Martínez-Piñeiro ◽

Axel Heidenreich ◽

Marko Babjuk ◽

Marc Colombel ◽

...

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

Lessons Learned ◽

Invasive Bladder Cancer ◽

Phase 2 ◽